Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

Press Release

  • 09 December 2019
    HitGen Announces Strategic Collaboration with Janssen to Design and Build Novel DNA-Encoded Libraries
    Chengdu, China, December 9th, 2019 – HitGen Inc. (“HitGen”) is pleased to announce that the company has entered into a strategic collaboration with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to design and build novel DNA-encoded libraries (“DELs”) to discover unique small molecule assets. The collaboration will apply HitGen’s advanced technology platform and research capabilities in the design and synthesis of multiple proprietary DELs for Janssen drug discovery and development efforts.The collaboration was facilitated by Johnson & Johnson Innovation and builds upon the success of earlier agreements for the identification of hits using HitGen’s platform for various priority targets.
  • 12 November 2019
    LEO Pharma Exercises Option with HitGen to License Compounds
    Ballerup, Denmark and Chengdu, China, November 12, 2019 – LEO Pharma A/S and HitGen Inc. are pleased to announce that HitGen and LEO Pharma expands their collaboration with a license to develop a novel class of drugs for a dermatology indication.
  • 16 October 2019
    HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Galapagos NV
    Chengdu, China,October 16th,2019 – HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Galapagos NV to identify potential small molecule leads against targets of interest to Galapagos NV.In this collaboration,HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement,HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Galapagos NV.
  • 03 June 2019
    HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Gilead Sciences
    Chengdu, China,June 3rd, 2019-HitGen Inc today announced that it has entered into adrug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead.In this collaboration,HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement,HitGen will receive an undisclosed upfront payment and will be eligible formilestone payments from Gilead.
  • 18 April 2019
    HitGen Announces Achievement of Milestone from DEL Discovery Alliance with Merck & Co., Inc., Kenilworth, NJ., USA
    Kenilworth, N.J., U.S.A. CHENGDU, CHINA – April 18, 2019, HitGen Inc., announced today that it has achieved a milestone in its discovery alliance with Merck & Co. Inc., Kenilworth NJ, USA, known as MSD outside the United States and Canada. The milestone was for the identification of candidates meeting pre-defined criteria, representing the 3rd discovery program between the two companies for which HitGen has achieved this milestone. This achievement entitles HitGen to receive an undisclosed payment per the research collaboration agreement between both companies announced March 14, 2017.
  • 11 April 2019
    HitGen and Kaken Enter Into License Agreement
    Chengdu, China, April 11, 2019 HitGen Inc. announced today that HitGen Inc. and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs. The licensed compounds were identified using HitGen’s leading technology platform, which involved screening large DNA encoded libraries, containing over 400 billion of small molecules with drug-like properties synthesized on chemically diverse scaffolds. A number of novel small molecule leads for an undisclosed target nominated by Kaken were the subject of this license agreement.
  • 25 March 2019
    HitGen and Almirall Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
    Chengdu, China, March 25, 2019, HitGen Ltd announced that the company has entered into a research collaboration with Almirall to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Almirall. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Almirall. Specific financial details were not disclosed.
  • 13 March 2019
    HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
    CHENGDU and MUMBAI –March 13, 2019,HitGenLtd. and Sun Pharma Advanced Research Company Ltd. (SPARC)(Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) todayannounced a research collaboration toidentifynovel small molecule leads for targets of interest.Under this collaboration,HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads forSPARC. Under the terms of the agreement,HitGenwill receive upfrontpaymentand will be eligible for certainmilestone payments.
  • 20 December 2018
    HitGen and Bayer Enter DNA-Encoded Library Based Research Collaboration
    Chengdu, China, December 20, 2018, HitGen Ltd announced that the company has entered into a research collaboration with the Crop Science division of Bayer to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Bayer research endeavours. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Bayer. Specific financial details were not disclosed.
  • 11 December 2018
    HitGen and Mitsubishi Tanabe Pharma Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
    Chengdu, China, December 11, 2018, HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (President and CEO: Masayuki Mitsuka; Headquarters: Osaka; “MTPC”) to identify novel small molecule leads for targets of interest. According to the agreement, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis, and screening system, to discover novel lead compounds. The collaboration will use HitGen’s libraries containing more than 300 billion individually DNA-encoded compounds. The DNA encoding of molecules enables screening and analysis of vast chemical space, supporting MTPC’s aim to increase success rates for the generation of target leads for new drugs and to drastically shorten screening timelines for expanding MTPC’s pipeline. Under the terms of the agreement, HitGen will receive technology access and research support payments, and be eligible for milestone payments from MTPC. Financial details were not disclosed.

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
验证码
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information